Fotivda® (tivozanib) – New drug approval
March 10, 2021 - AVEO Oncology announced the FDA approval of Fotivda (tivozanib), for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
Download PDF
